Paradigm Biopharmaceuticals (ASX:PAR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Paradigm Biopharmaceuticals (ASX:PAR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notice under Section 708A
Notification regarding unquoted securities - PAR
Drawdown of Tranche 4 under the Convertible Note Facility
Paradigm Biopharma completes US$3 million drawdown under Convertible Note Facility to support Phase 3 trial
Change of Director's Interest Notice
Notification of cessation of securities - PAR
Notification of cessation of securities - PAR
Change of Director's Interest Notice
Change of Director's Interest Notice
Application for quotation of securities - PAR
Listing of Options - Top 20 Holders and Distribution Reports
Application for quotation of securities - PAR
PAR Completes Enrolment in Pivotal Phase 3
Paradigm completes enrolment in Phase 3 osteoarthritis trial, on track for 2027 results
Options Prospectus
Results of Meeting
Change of Director's Interest Notice
Change of Director's Interest Notice
Ceasing to be a substantial holder
Notification of cessation of securities - PAR
Application for quotation of securities - PAR
Application for quotation of securities - PAR
Update - Proposed issue of securities - PAR
Results of Share Purchase Plan
Paradigm Biopharma raises $21.375 million through oversubscribed SPP and Placement
Notice of General Meeting/Proxy Form
Becoming a substantial holder
Cleansing Notice
Application for quotation of securities - PAR
Variation to Convertible Securities Agreement
Share Purchase Plan - Offer Booklet
DSMB 20% Review Supports Phase 3, Moldova Activated
Paradigm's Phase 3 OA Trial Passes 20% Safety Review, Moldova Site Activated for Final Recruitment
OARSI Theatre Presentation Showcases iPPS Biomarker Data
March 2026 Quarterly Activities Report & Appendix 4C
Paradigm Biopharma hits 50% dosing in Phase 3 OA trial, secures A$45m funding, targets August interim analysis
Proposed issue of securities - PAR
Proposed issue of securities - PAR
Upsized $14M Placement Extends Runway Post IA
Paradigm Biopharma upsizes $14M placement, launches $2M SPP to fund Phase 3 knee OA trial through interim analysis
Trading Halt